This review is of a recent retrospective study that analysed data from six prospective clinical trials of sunitinib for treatment of metastatic renal cell carcinoma to characterise heterogeneity of patients with an intermediate prognosis and determine whether it affects response.
Independent commentary is provided by Associate Professor Arun Azad, a medical oncologist holding appointments at Peter MacCallum Cancer Centre and the University of Melbourne.
Please login below to download this issue (PDF)